#1 Clinical Trials Search in Europe

Piperacillin Monohydrate

This article discusses clinical trials investigating the use of Piperacillin Monohydrate, often in combination with Tazobactam, for treating sepsis and respiratory conditions. These studies aim to optimize dosing strategies, compare effectiveness with other antibiotics, and examine the drug’s pharmacokinetics in different patient populations, including those with chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).

Table of Contents

What is Piperacillin Monohydrate?

Piperacillin Monohydrate is an important antibiotic medication that belongs to the class of drugs called beta-lactam antibiotics[1]. It is often used in combination with another drug called tazobactam, which helps prevent bacteria from becoming resistant to piperacillin. This combination is known as Piperacillin/Tazobactam.

What is Piperacillin Monohydrate Used For?

Piperacillin Monohydrate is primarily used to treat serious bacterial infections. It is particularly effective against a wide range of bacteria, making it useful for treating various types of infections[1]. Some of the conditions it may be used to treat include:

  • Sepsis: A life-threatening condition caused by the body’s response to infection[1]
  • Pneumonia: An infection that inflames the air sacs in one or both lungs
  • Intra-abdominal infections: Infections within the abdomen
  • Skin and soft tissue infections: Infections affecting the skin and underlying tissues

It’s important to note that Piperacillin/Tazobactam is often used in hospital settings, particularly in intensive care units (ICUs), for patients with severe infections[2].

How is Piperacillin Monohydrate Administered?

Piperacillin Monohydrate is typically administered intravenously (through a vein) in a hospital setting[1]. The dosage and duration of treatment can vary depending on several factors, including:

  • The type and severity of the infection
  • The patient’s age and weight
  • The patient’s kidney function

In some cases, Piperacillin/Tazobactam may be given as a continuous infusion over 24 hours, while in others, it may be administered in multiple doses throughout the day[2].

Current Clinical Trials

Several clinical trials are currently underway to further investigate the use of Piperacillin/Tazobactam in various medical conditions:

  1. EMPRESS Trial: This study is comparing the effectiveness of Piperacillin/Tazobactam with another antibiotic called meropenem in treating adults with sepsis[1].
  2. BuLLSEYE Study: This trial is investigating new dosing strategies for several antibiotics, including Piperacillin/Tazobactam, in critically ill patients with sepsis[2].
  3. Pharmacokinetics in Children with External Ventricular Drain: This study is examining how Piperacillin/Tazobactam and other antibiotics behave in the cerebrospinal fluid of children with external ventricular drains[3].
  4. Pulmonary Pharmacokinetics Study: This research is looking at how Piperacillin/Tazobactam concentrates in the lungs of patients with chronic obstructive pulmonary disease (COPD) or cystic fibrosis[4].

These studies aim to improve our understanding of how to best use Piperacillin/Tazobactam in different patient populations and conditions.

Potential Side Effects

Like all medications, Piperacillin Monohydrate can cause side effects. Some potential side effects include:

  • Allergic reactions: In rare cases, patients may experience anaphylactic shock, a severe allergic reaction[1]
  • Gastrointestinal issues: Some patients may develop pseudomembranous colitis, an inflammation of the colon[1]
  • Skin reactions: In very rare cases, a severe skin reaction called toxic epidermal necrolysis may occur[1]
  • Fungal infections: Prolonged use of antibiotics like Piperacillin/Tazobactam may lead to invasive fungal infections in some cases[1]

It’s important to note that serious side effects are rare, and the benefits of using Piperacillin/Tazobactam in treating severe infections often outweigh the risks. However, patients should always discuss potential side effects with their healthcare provider.

Trial Focus Patient Population Primary Outcome Key Secondary Outcomes
Comparing Meropenem vs Piperacillin/Tazobactam Adults with sepsis 30-day mortality Serious adverse reactions, resistant bacteria, days alive without life support
Optimizing antibiotic dosing Critically ill sepsis patients in ICU 28-day mortality Antibiotic blood levels, infection parameters, hospital/ICU length of stay
Pharmacokinetics in cerebrospinal fluid Children with external ventricular drain Drug concentration parameters in CSF Pharmacokinetic/pharmacodynamic parameters, target attainment analysis
Pulmonary pharmacokinetics COPD or CF patients undergoing lung transplantation Antibiotic concentrations in lung tissue Comparison of measurement methods (ELF, tissue biopsy, microdialysis)

FAQ

  • What is Piperacillin Monohydrate? Piperacillin Monohydrate is an antibiotic often used in combination with Tazobactam. It belongs to the beta-lactam class of antibiotics and is effective against a wide range of bacterial infections.
  • What conditions are being studied in these clinical trials? The clinical trials are primarily focusing on sepsis, including septic shock, as well as respiratory conditions such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).
  • How is Piperacillin/Tazobactam being compared to other antibiotics? In one trial, Piperacillin/Tazobactam is being compared to Meropenem for treating sepsis in critically ill adults to assess their effects on mortality and other patient-important outcomes.
  • What is the main goal of the dosing strategy study? The dosing strategy study aims to determine if using a new dosing approach can improve clinical outcomes for sepsis patients in the Intensive Care Unit (ICU).
  • How is the drug's effectiveness being measured in these trials? The drug's effectiveness is being measured through various outcomes, including mortality rates, length of hospital stay, antibiotic blood levels, infection parameters, and quality of life assessments.

Ongoing Clinical Trials on Piperacillin Monohydrate

  • Study of Piperacillin/Tazobactam and Levofloxacin for Patients with COPD or Cystic Fibrosis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study on Post-Surgery Antibiotic Use for Patients with Biliary Stents Undergoing Pancreaticoduodenectomy: Piperacillin and Tazobactam Evaluation

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on Optimizing Initial Dosing of Flucloxacillin and Drug Combination for Critically Ill Patients with Sepsis in the ICU

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effectiveness and Safety of Extended vs. Intermittent Infusion of Meropenem in Critically Ill Children with Suspected or Proven Infection

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Hungary

  • Study on How Antibiotics Work in the Spinal Fluid of Children with Brain Drains: Cefuroxime, Vancomycin, and Gentamicin with a Drug Combination

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria

Glossary

  • Sepsis: A life-threatening condition that occurs when the body's response to infection causes widespread inflammation and organ dysfunction.
  • Septic shock: A severe form of sepsis characterized by dangerously low blood pressure and organ failure.
  • COPD: Chronic Obstructive Pulmonary Disease, a group of lung diseases that cause airflow blockage and breathing-related problems.
  • Cystic Fibrosis (CF): An inherited disorder that causes thick, sticky mucus to build up in the lungs and other organs.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Epithelial Lining Fluid (ELF): The thin layer of fluid that covers the surface of the lungs' air sacs, important for studying drug concentrations in lung tissue.
  • In-vivo microdialysis: A technique used to measure drug concentrations in living tissue over time.
  • Beta-lactam antibiotics: A class of antibiotics that includes penicillins and cephalosporins, characterized by their molecular structure.
  • Empirical treatment: Treatment based on clinical experience and observation rather than confirmed laboratory results.
  • SOFA score: Sequential Organ Failure Assessment score, used to track a patient's status during their stay in an intensive care unit.

References

  1. http://clinicaltrials.eu/trial/study-comparing-meropenem-and-piperacillin-tazobactam-for-adults-with-sepsis/
  2. http://clinicaltrials.eu/trial/study-on-optimizing-initial-dosing-of-flucloxacillin-and-drug-combination-for-critically-ill-patients-with-sepsis-in-the-icu/
  3. http://clinicaltrials.eu/trial/study-on-how-antibiotics-work-in-the-spinal-fluid-of-children-with-brain-drains-cefuroxime-vancomycin-and-gentamicin-with-a-drug-combination/
  4. http://clinicaltrials.eu/trial/study-of-piperacillin-tazobactam-and-levofloxacin-for-patients-with-copd-or-cystic-fibrosis/